Drugs / Midomafetamine
Midomafetamine
also known as
midomafetamine HCl · MDMA · Methylenedioxymethamphetamine · MDMA HCl · midomafetamine hydrochloride salt
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06565494 | Aug 2024 → Aug 2026 overdue | narcissistic personality disorder | University of Washington | Active not recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07584720 | Apr → Jul 2026 overdue | — | Resilient Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03606538 | Mar 2026 → Dec 2028 expected | — | Resilient Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06772753 | Feb 2025 → Jun 2027 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT04073433 | Dec 2024 → Dec 2025 | — | Resilient Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03181763 | Mar 2017 → Aug 2020 | — | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 213 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04454684 | Feb 2026 → Aug 2028 | anorexia nervosa, binge eating disorder | Resilient Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT06418178 | Jun 2025 → Oct 2029 expected | post-traumatic stress disorder | Bronx VA Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05173831 | Sep 2023 → Dec 2024 | post-traumatic stress disorder | Resilient Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT05732155 | Jun 2023 → Jun 2027 expected | post-traumatic stress disorder | HaEmek Medical Center, Israel | Recruiting | No outcome recorded |
| Phase 2 | NCT04968938 | Aug 2022 → Aug 2023 | post-traumatic stress disorder | Resilient Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT04030169 | Jun 2020 → Dec 2023 | post-traumatic stress disorder | MAPS Europe B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03485287 | Mar 2018 → Jun 2019 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03282123 | Nov 2017 → Aug 2019 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02427568 | May 2015 → Apr 2017 | anxiety | Resilient Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01958593 | Oct 2014 → Sep 2015 | post-traumatic stress disorder | Resilient Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02008396 | Apr 2014 → Apr 2017 | — | Resilient Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01458327 | Dec 2010 → Jun 2014 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00402298 | May 2007 → Mar 2009 | post-traumatic stress disorder | Resilient Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07118839 | May 2026 → May 2030 expected | alcohol-related disorders, post-traumatic stress disorder | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT04714359 | Mar 2021 → Nov 2023 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04077437 | Sep 2020 → Oct 2022 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03537014 | Nov 2018 → Aug 2020 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT04438512 | — | post-traumatic stress disorder | Resilient Pharmaceuticals | No longer available | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT05147402 Comparator | Jul → Dec 2022 | — | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01404754 Comparator | Apr 2011 → Aug 2022 | — | Resilient Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04784143 Comparator | Nov 2021 → Jun 2024 | post-traumatic stress disorder | Resilient Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01793610 Comparator | May 2013 → Dec 2015 | post-traumatic stress disorder | Resilient Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-24 | Definium Therapeutics US, Inc. | Results MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting definiumtx.com ↗
This study demonstrated that administration of MM-402 increased social interaction in a characterized preclinical model of ASD. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-24 | Definium Therapeutics US, Inc. | MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting definiumtx.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Midomafetamine | “An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose...” NCT01793610 ↗23“180 mg midomafetamine hydrochloride salt (MDMA HCl) administered orally” NCT07118839 ↗ |
| Known as | MDMA | “This open-label, proof-of-concept pilot study will assess the efficacy and safety of midomafetamine (MDMA) - assisted therapy (AT) for participants diagnosed with pathological...” NCT06565494 ↗1“Drug: Methylenedioxymethamphetamine (MDMA)” NCT06772753 ↗ |
| Known as | MDMA HCl | “180 mg midomafetamine hydrochloride salt (MDMA HCl) administered orally” NCT07118839 ↗ |
| Known as | Methylenedioxymethamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06772753 ↗ |
| Known as | midomafetamine HCl | “The treatment consists of an initial dose of midomafetamine HCl (80 or 120 mg), followed by a supplemental dose (40 or 60 mg) unless contraindicated, administered with...” NCT04714359 ↗4“Participants who meet study criteria will receive a single dose of 80 mg midomafetamine HCl on the first day of a three-day stay at the study site.” NCT03606538 ↗ “40 mg midomafetamine HCl administered orally” NCT07118839 ↗ |
| Known as | midomafetamine hydrochloride salt | “180 mg midomafetamine hydrochloride salt (MDMA HCl) administered orally” NCT07118839 ↗ |
| Route | Oral | “midomafetamine HCl orally” NCT00402298 ↗ |